Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure
Kawanishi, N., Sugimoto, T., Shibata, J., Nakamura, K., Masutani, K., Ikuta, M., Hirai, H.(2006) Bioorg Med Chem Lett 16: 5122-5126
- PubMed: 16876403 
- DOI: https://doi.org/10.1016/j.bmcl.2006.07.026
- Primary Citation of Related Structures:  
2DS1 - PubMed Abstract: 
The design of a novel series of cyclin-dependent kinase (CDK) inhibitors containing a macrocyclic quinoxaline-2-one is reported. Structure-based drug design and optimization from the starting point of diarylurea 2, which we previously reported as a moderate CDK1,2,4,6 inhibitor [J. Biol.Chem.2001, 276, 27548], led to the discovery of potent CDK1,2,4,6 inhibitor that were suitable for iv administration for in vivo study.
Organizational Affiliation: 
Department of Medicinal Chemistry, Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Okubo-3, Tsukuba 300-2611, Ibaraki, Japan. nobuhiko_kawanishi@merck.com